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Friedreich ataxia (FRDA) is a lethal autosomal recessive neurodegenerative disorder
caused primarily by a homozygous GAA repeat expansion mutation within the first intron of
the FXN gene, leading to inhibition of FXN transcription and thus reduced frataxin protein
expression. Recent studies have shown that epigenetic marks, comprising chemical
modifications of DNA and histones, are associated with FXN gene silencing. Such
epigenetic marks can be reversed, making them suitable targets for epigenetic-based
therapy. Furthermore, since FRDA is caused by insufficient, but functional, frataxin protein,
epigenetic-based transcriptional re-activation of the FXN gene is an attractive therapeutic
option. In this review we summarize our current understanding of the epigenetic basis of
FXN gene silencing and we discuss current epigenetic-based FRDA therapeutic strategies.
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INTRODUCTION
Friedreich ataxia (FRDA) is an autosomal recessive neurodegener-
ative mitochondrial disorder caused primarily by a homozygous
GAA repeat expansion mutation within intron 1 of the frataxin
gene (FXN) located on chromosome 9q21.1 (Campuzano et al.,
1996). Unaffected individuals have up to 43 GAA repeats, while
affected individuals have 44–1700 GAA repeats, most commonly
between 600 and 900 GAA repeats (Sharma et al., 2004; Pandolfo,
2008). The effect of the GAA repeat expansion is to decrease
expression of the essential and ubiquitously expressed mitochon-
drial protein frataxin (Campuzano et al., 1997). However, asymp-
tomatic carriers produce about 50% frataxin levels compared to
unaffected individuals (Pianese et al., 2004). Therefore, drugs that
induce frataxin expression, at least to the levels of healthy carri-
ers, would be beneficial. The FXN gene spans 95 kb of genomic
DNA and contains seven exons, 1–5a, 5b, and 6 (Campuzano
et al., 1996). The first five exons are transcribed to produce a 210
amino acid major isoform of frataxin, but rarely exon 5b can be
transcribed by alternative splicing to produce a 171 amino acid
protein. In addition, a recent study has identified two novel tis-
sue specific transcript variants, encoding two isoforms of frataxin
that lack the mitochondrial targeting sequence and are therefore
different from the canonical transcript (Xia et al., 2012).
Reduced levels of frataxin in FRDA patients are associated
with defects of iron-sulfur cluster (ISC) biosynthesis (Bradley
et al., 2000), mitochondrial iron accumulation in heart and den-
tate nucleus (Foury and Cazzalini, 1997; Waldvogel et al., 1999;
Koeppen et al., 2007), and increased susceptibility to oxidative
stress (Wong et al., 1999). The main pathological effects are loss
of large sensory neurons in the dorsal root ganglia (DRG) and
degenerative atrophy of the posterior columns of the spinal cord,
contributing to symptoms of progressive ataxia, muscle weakness,
and sensory deficit. There is also pathological involvement of
non-neuronal tissues, with hypertrophic cardiomyopathy a com-
mon feature, and diabetes mellitus identified in approximately
10% of FRDA patients (Schulz et al., 2009). Affected individuals
generally die in early adulthood from the associated heart disease
and at present there is no effective therapy for FRDA. Therefore,
there is a high unmet clinical need to develop a therapy for this
devastating disorder.
Although the exact mechanism by which the GAA repeat
expansion leads to decreased frataxin expression is not known,
two hypotheses have been proposed (Figure 1). Firstly, evidence
from in vitro and cell transfection studies suggests that the
GAA repeat expansion may adopt abnormal non-B DNA struc-
tures (triplexes or “sticky DNA”) or DNA•RNA hybrid structures
(R-loops), which impede the process of RNA polymerase II and
thus reduce FXN gene transcription (Grabczyk et al., 2007; Wells,
2008). Secondly, there is evidence that GAA repeat expansions
can produce heterochromatin-mediated gene silencing effects
(Saveliev et al., 2003). Consistent with the latter hypothesis, sev-
eral FRDA disease-related epigenetic changes have been identified
in the immediate vicinity of the expanded GAA repeats of the
FXN gene and these changes will be discussed further within this
review.
EPIGENETIC CHANGES ASSOCIATED WITH FRDA
Epigenetic mechanisms, including DNAmethylation and hydrox-
ymethylation, post-translational histone modifications, chro-
matin remodeling, and non-coding RNA effects, produce effects
on gene expression without involving changes in the primary
DNA sequence. The potential role of epigenetic mechanisms
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FIGURE 1 | Models of FXN gene silencing in FRDA. (A) Unaffected
individuals, who carry up to 43 GAA•TTC repeats, contain active histone
marks of gene transcription initiation and elongation at the FXN promoter and
intron 1 regions. (B) In FRDA patients, the presence of large GAA•TTC repeat
expansion leads to FXN gene silencing by two potential mechanisms: (i) the
GAA•TTC repeat may adopt abnormal non-B DNA structures (triplexes) or
DNA•RNA hybrid structures (R loops), which impede the process of RNA
polymerase and thus reduce FXN gene transcription, (ii) increased levels of
DNA methylation and HP1 and significant enrichment of repressive histone
marks at the FXN gene trigger heterochromatin formation that may lead to
more pronounced FXN gene silencing. This image was adapted from
Festenstein (2006); Wells (2008); Chan et al. (2013).
in FRDA disease was first suggested by the finding that
long GAA repeats could suppress the expression of a nearby
heterochromatin-sensitive cell surface reporter gene in trans-
genic mice by position effect variegation (PEV) (Saveliev et al.,
2003). Further studies of FRDA cells, tissues, and mouse models
have subsequently led to the identification of epigenetic changes,
including DNA methylation and hydroxymethylation, histone
deacetylation, and histone methylation, which may be involved
in FXN gene silencing in FRDA (Table 1).
DNA METHYLATION AND HYDROXYMETHYLATION
DNA methylation is carried out by DNA methyltransferase
(DNMT) enzymes, which catalyze the conversion of cytosine
to 5′-methylcytosine (5mC), predominantly within CpG dinu-
cleotides (Robertson, 2001). In mammals, the DNMT family
includes three functional proteins: DNMT1 preferentially methy-
lates hemi-methylated DNA and is thus responsible for methy-
lation during DNA replication (Pradhan et al., 1999), while
DNMT3a and DNMT3b have an equal preference for hemi-
methylated and non-methylated DNA and so have been classified
as de novomethyltransferases (Okano et al., 1999). Studies investi-
gating the DNA methylation profiles of transcriptionally silenced
genes have revealed a strong correlation between promoter DNA
methylation and transcriptional silencing. However, it has also
been reported that intragenic DNAmethylation can contribute to
transcriptional gene silencing (Lorincz et al., 2004). More recent
studies have revealed the existence of an alternative modification,
5′-hydroxymethylcytosine (5hmC), which is formed by oxidation
of 5mC by ten-eleven translocation (TET) enzymes (Kriaucionis
and Heintz, 2009; Tahiliani et al., 2009). 5hmC may either be an
intermediate in the removal of 5mC by an active demethylation
process (Guo et al., 2011) or it may be an epigenetic modifi-
cation in its own right, regulating chromatin or transcriptional
factors (Szulwach et al., 2011). Therefore, it is possible that 5hmC
may prove to be involved in epigenetic-based diseasemechanisms,
such as those proposed for FRDA.
Initial investigations of DNAmethylation within the FXN gene
by Usdin and colleagues revealed hypermethylation of specific
CpG sites upstream of the GAA repeat sequence in FRDA patient-
derived lymphoblastoid cells compared to cells derived from
unaffected individuals (Greene et al., 2007). In particular, three
out of 15 CpG residues that span a 700 bp region upstream of the
GAA repeat were found to be unmethylated, or sparsely methy-
lated, in unaffected cells, but highly methylated in FRDA cells.
Studies by our laboratory also revealed significantly increased
DNA methylation at the same upstream GAA repeat region in
FRDA patient autopsy brain, heart, and cerebellum tissues, with
similar findings in tissues of FRDA YAC transgenic mice (Al-
Mahdawi et al., 2008). Subsequently, a study of FRDA patient
blood samples showed that the degree of DNA methylation at the
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Table 1 | Epigenetic changes in tissues, cells, and animal models of FRDA.
Chromatin changea Location FRDA tissue, cell, or animal model References
5mC ↑ GAA upstream FRDA patient tissues, primary lymphocytes,
lymphoblasts, FXN YAC transgenic mice
Greene et al., 2007; Al-Mahdawi et al., 2008,
2013; Evans-Galea et al., 2012
5hmC ↑ GAA upstream FRDA patient tissues Al-Mahdawi et al., 2013
H3K4me2/3 ↓ FXN promoter and exon 1 Lymphoblasts Punga and Buhler, 2010; Kim et al., 2011;
Kumari et al., 2011
GAA upstream Lymphoblasts Kim et al., 2011; Kumari et al., 2011
GAA downstream Lymphoblasts Kim et al., 2011; Kumari et al., 2011
H3K9me2/3 ↑ FXN 5′UTR/promoter Primary fibroblasts, lymphoblasts De Biase et al., 2009; Kim et al., 2011
GAA upstream Lymphoblasts, FXN YAC transgenic mice, KIKI mice Herman et al., 2006; Al-Mahdawi et al.,
2008; Rai et al., 2008; Punga and Buhler,
2010; Kim et al., 2011; Kumari et al., 2011;
Chan et al., 2013
GAA downstream FRDA patient tissues, FXN YAC transgenic mice,
lymphoblasts
Herman et al., 2006; Al-Mahdawi et al.,
2008; Punga and Buhler, 2010; Kim et al.,
2011; Kumari et al., 2011; Chan et al., 2013
H3K27me3 ↑ FXN 5′UTR/promoter Primary fibroblasts, lymphoblasts De Biase et al., 2009; Kim et al., 2011
GAA upstream Lymphoblasts Kim et al., 2011; Chan et al., 2013
GAA downstream Lymphoblasts Kim et al., 2011; Chan et al., 2013
H3K36me3 ↓ GAA upstream Lymphoblasts Punga and Buhler, 2010; Kim et al., 2011;
Kumari et al., 2011
GAA downstream Lymphoblasts Punga and Buhler, 2010; Kumari et al., 2011;
Kim et al., 2011
H3K79me2 ↓ GAA upstream Lymphoblasts Kim et al., 2011
GAA downstream Lymphoblasts Kim et al., 2011
H4K20me3 ↑ GAA upstream Lymphoblasts Kim et al., 2011
GAA downstream Lymphoblasts Kim et al., 2011
H3K9ac ↓ FXN promoter FRDA patient brain tissue, lymphoblasts Al-Mahdawi et al., 2008; Kumari et al., 2011
GAA upstream FRDA patient tissues, lymphoblasts, FXN YAC
transgenic mice, KIKI mice
Herman et al., 2006; Al-Mahdawi et al.,
2008; Kumari et al., 2011
GAA downstream FRDA patient tissues, lymphoblasts, FXN YAC
transgenic mice
Herman et al., 2006; Al-Mahdawi et al.,
2008; Kumari et al., 2011
H3K14ac ↓ FXN promoter FRDA patient tissues Al-Mahdawi et al., 2008
GAA upstream Lymphoblasts, KIKI mice Rai et al., 2008; Kumari et al., 2011
GAA downstream Lymphoblasts, FXN YAC transgenic mice Kumari et al., 2011
H4K5ac ↓ FXN promoter Lymphoblasts Kumari et al., 2011
GAA upstream Lymphoblasts, KIKI mice Herman et al., 2006; Rai et al., 2008; Kumari
et al., 2011
GAA downstream FRDA patient tissues, FXN YAC transgenic mice,
lymphocytes
Al-Mahdawi et al., 2008; Rai et al., 2008;
Kumari et al., 2011
(Continued)
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Table 1 | Continued
Chromatin changea Location FRDA tissue, cell, or animal model References
H4K8ac ↓ GAA upstream Lymphoblasts, FRDA patient tissues, KIKI mice Herman et al., 2006; Al-Mahdawi et al.,
2008; Rai et al., 2008; Kumari et al., 2011
GAA downstream Lymphoblasts, FRDA patient tissues Herman et al., 2006; Kumari et al., 2011
H4K12ac ↓ FXN promoter Lymphoblasts Herman et al., 2006
GAA upstream Lymphoblasts, FRDA patient tissues, FXN YAC
transgenic mice
Herman et al., 2006; Al-Mahdawi et al., 2008
GAA downstream Lymphoblasts, FRDA patient tissues, FXN YAC
transgenic mice
Herman et al., 2006; Al-Mahdawi et al., 2008
H4K16ac ↓ FXN promoter Lymphoblasts Rai et al., 2008; Kumari et al., 2011
GAA upstream Lymphoblasts, FRDA patient tissues, FXN YAC
transgenic mice, KIKI mice
Herman et al., 2006; Al-Mahdawi et al.,
2008; Rai et al., 2008; Kumari et al., 2011
GAA downstream Lymphoblasts, FRDA patient tissues, FXN YAC
transgenic mice, KIKI mice
Herman et al., 2006; Al-Mahdawi et al.,
2008; Rai et al., 2008; Kumari et al., 2011
a↓, reduced; ↑, increased; H, histone; K, lysine; me2, dimethylation; me3, trimethylation; ac, acetylation.
FXN upstream GAA repeat region correlates with the length of
the GAA repeats and inversely correlates with the age of disease
onset (Castaldo et al., 2008). Furthermore, analysis of blood and
buccal cells from a large cohort of FRDA patients showed that
the level of DNA methylation in FRDA patients is significantly
elevated in the same upstream GAA repeat region and inversely
correlated with FXN expression levels (Evans-Galea et al., 2012).
More recently, our laboratory has shown that, for at least one CpG
site within the upstream GAA repeat region, the increased level
of DNAmethylation predominantly comprises 5hmC rather than
5mC (Al-Mahdawi et al., 2013). Thus, FRDA can now be grouped
together with other TNR expansion diseases in which an associ-
ation with DNA methylation and hydroxymethylation has been
observed (Table 1, Figure 2).
POST-TRANSLATIONAL HISTONE MODIFICATIONS
The nucleosome consists of an octamer of four pairs of his-
tone proteins, H2A, H2B, H3, and H4, surrounded by 147 bp
of DNA (Kouzarides, 2007). Histone proteins contain a globular
C-terminal domain and an unstructured N-terminal tail, which
can containmany differentmodified residues. Histone acetylation
at lysine residues is regulated by two distinct families of enzymes
with opposing actions, histone acetyltransferases (HATs) and
histone deacetylases (HDACs). Similarly, histone lysine methyla-
tion is controlled by histone methyltransferases (HMTases) and
histone demethylases (HDMs), which have been linked to a num-
ber of cellular processes including transcriptional activation and
repression (Kouzarides, 2007). HATs are diverse set of enzymes
that are grouped into two different families based on their cat-
alytic domains: Gcn5 N-acetyltransferases (GNATs, e.g., Gcn5
and PCAF) andMYST HATs (e.g., Morf and Ybf2) (Kimura et al.,
2005). Each HAT is usually capable of modifying several different
histone residues. Eighteen different HDACs have been identified
in mammals and these have been divided into four classes. Class I
consists of HDACs 1, 2, 3, and 8, which are similar to yeast RPD3
deacetylase. Class II consists of HDACs 4, 5, 7, and 9, which have
homology to the yeast HDAC Had-1 gene. Class III HDACs, also
known as sirtuins, which have homology to the Yeast Sir2 gene,
include sirtuin 1–7. Lastly, class IVHDACs consists of only HDAC
11. HMTases are divided into lysine-specific and arginine-specific
groups. They have great specificity and usually modify only one
particular histone residue (Kouzarides, 2007). The HDMs are
classified into two distinct enzyme families: the nuclear amine
oxidase homologs (e.g., LSD1) and the JmjC-domain proteins
(e.g., JHDM1) (Kouzarides, 2007).
In mammals, heterochromatin formation and gene silencing
is associated with hypoacetylation of certain histone residues,
particularly H3K9, together with increased methylation of his-
tone residues, including H3K9me2, H3K9me3, H3K27me3, and
H4K20me3 (Kourmouli et al., 2004; Martin and Zhang, 2005;
Jenuwein, 2006). Such histonemodifications have now been iden-
tified within the FXN gene in FRDA cells, tissues, and mouse
models, predominantly at the region immediately upstream of
the expanded GAA repeats, indicating that the FXN gene is sub-
ject to heterochromatin silencing (Sandi et al., 2013) (Table 1,
Figure 1). Histonemodifications at the FXN locus were first iden-
tified by Gottesfeld and colleagues, who reported lower levels
of several acetylated H3 and H4 lysine residues, together with
increased H3K9me2 and H3K9me3 in the upstream GAA regions
of FRDA lymphoblastoid cells (Herman et al., 2006). Usdin and
colleagues then reported increased H3K9me2 levels within FXN
intron 1 in FRDA lymphoblastoid cells (Greene et al., 2007) and
our laboratory reported changes of histone modifications at the
FXN promoter, upstream, and downstream GAA repeat regions
in FRDA patient and YAC transgenic mouse brain tissues (Al-
Mahdawi et al., 2008). Subsequently, Bidichandani and colleagues
reported that FRDA patient fibroblasts have significantly higher
levels of H3K9me3 and H3K27me3 at the FXN 5′ UTR region,
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FIGURE 2 | The position of DNA methylation, hydroxymethylation,
and CTCF binding sites within the FXN gene. (A) Unaffected:
normal-sized GAA repeat (B) FRDA: GAA repeat expansion. Gray
boxes represent regions of disease-associated DNA methylation and
hydroxymethylation. Arrow marks represent the directions and levels
of transcription for FXN and FAST-1. Blue bars represent exons of
the FXN gene. Red triangles indicate GAA repeats within intron 1 of
the FXN gene.
coupled with elevated levels of heterochromatin protein 1 (HP1),
compared to normal fibroblasts (De Biase et al., 2009). More
recently, Chan and colleagues have identified increased H3K9me3
and H3K27me3 at the upstream and downstream GAA repeat
regions in FRDA lymphoblasts (Chan et al., 2013).
In contrast, histone modifications such as H3K4me3,
H3K36me3, and H3K79me3 are associated with a more open
chromatin state and active gene expression. H3K4me3 is par-
ticularly associated with initiation of gene transcription, while
H3K36me3 and H3K79me3 are associated with elongation of
gene transcription. Recent studies have shown decreased levels
of H3K36me3 and H3K79me3 at the upstream and downstream
GAA repeat regions of the FXN gene in FRDA cells, indicat-
ing that there is a defect in transcription elongation (Punga and
Buhler, 2010; Kim et al., 2011; Kumari et al., 2011). Decreased
levels of H3K4me3 have also been identified at the upstream
GAA repeat region, but not at the promoter region, which
suggests a more pronounced defect of the post-initiation and
elongation stages of FXN gene expression rather than an early
transcription initiation defect (Punga and Buhler, 2010; Kim
et al., 2011; Kumari et al., 2011) (Figure 1). In summary, there
is good evidence that reduction of frataxin protein expression
in FRDA is primarily caused by GAA repeat expansion-induced
transcriptional silencing, which is associated with specific post-
translational histone modifications.
ANTISENSE TRANSCRIPTION AND CTCF BINDING
Antisense RNA transcripts, which play a role in regulation of gene
expression, have previously been associated with TNR expan-
sion diseases such as Huntington disease (HD) (Chung et al.,
2011), FRAXA (Ladd et al., 2007; Khalil et al., 2008), DM1 (Cho
et al., 2005), SCA7 (Sopher et al., 2011), and SCA8 (Moseley
et al., 2006). Furthermore, the CCCTC-binding factor (CTCF)
protein, which can prevent the spreading of DNA methylation
(Filippova et al., 2005; Engel et al., 2006), has binding sites in the
repeat expansion flanking regions of several TNR disorders, such
as FRAXA (Ladd et al., 2007), DM1 (Filippova et al., 2001), and
SCA7 (Libby et al., 2008), and loss of CTCF binding at the DM1
CTG expansion is associated with the spread of heterochromatin
and DNA methylation (Cho et al., 2005). Bidichandani and col-
leagues have reported significantly increased levels of a frataxin
antisense transcript 1 (FAST1) in FRDA fibroblast cells, associ-
ated with depletion of CTCF binding at the 5′ UTR region of
the FXN gene (Figure 2), suggesting involvement of these fac-
tors in the heterochromatin and FXN gene silencing processes of
FRDA disease (De Biase et al., 2009). More recently, our labora-
tory has also reported increased expression of FAST1 in FRDA
mouse fibroblasts (Sandi et al., 2014) and reduced CTCF binding
at the 5′ UTR region of the FXN gene in FRDA cerebellum tis-
sue (Al-Mahdawi et al., 2013). Systematic genome-wide mapping
by ChIP analysis has shown that CTCF binds to tens of thou-
sands of genomic sites, often distal to transcription start sites
(TSS) of genes, but also at promoter and enhancer sequences
(Barski et al., 2007; Holwerda and De Laat, 2013). Thus, CTCF
can direct the interaction of tissue-specific enhancers with dif-
ferent neighboring promoters resulting in the regulation of gene
expression at a particular locus (Shen et al., 2012). The associa-
tion of CTCF binding at the 5′ UTR region of the FXN gene with
high levels of FXN expression and low levels of FAST1 expression
indicates that such CTCF control mechanisms might be in oper-
ation at the FXN locus. In a large proportion of cases, control
of CTCF binding has been shown to be sensitive to DNA methy-
lation (Wang et al., 2012). However, this is not likely to be the
case for FRDA, because FRDA-specific changes in DNA methyla-
tion have not been detected at the CTCF-binding site within the 5′
UTR region of the FXN gene (Al-Mahdawi et al., 2008; De Biase
et al., 2009). Therefore, further consideration of antisense tran-
scription, CTCF binding, and other associated factors are needed,
since they are likely to be highly relevant to the development of an
epigenetic-based therapy for FRDA.
EPIGENETIC-BASED THERAPIES FOR FRDA
DNA DEMETHYLATION THERAPIES
Since FRDA is associated with increased levels of DNA
methylation, one can propose the use of DNA demethylat-
ing agents to potentially activate a silenced FXN gene. DNA
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demethylating agents are generally divided into nucleoside analog
DNMT inhibitors and non-nucleoside analog DNMT inhibitors.
Nucleoside analog DNMT inhibitors, including 5-azacytidine
(5-aza-CR or Vidaza), 5-aza-2′-deoxycytidine (5-aza-CdR or
Decitabine), and Zebularine, are analogs of cytosine. 5-aza-CdR
is an FDA-approved drug that is used to treat leukemia patients
(Jain et al., 2009). Furthermore, treatment of lymphoblastoid cells
from FRAXA patients with 5-aza-CdR, either alone (Chiurazzi
et al., 1998) or in combination with HDAC inhibitors (Chiurazzi
et al., 1999), efficiently reverses the FMR1 promoter hyperme-
thylation and restores mRNA and protein levels to normal. Such
studies have led to the consideration of DNA demethylating
agents as a potential therapy for neurodegenerative disorders.
Thus, far, there have been no reports of describing the use of
DNA demethylating agents as a therapeutic approach for FRDA,
mainly due to the lack of evidence for a causal link between DNA
methylation and FXN gene silencing. However, DNA demethy-
lating agents, such as 5-aza-CdR, Zebularine, or the oligonu-
cleotide antisense inhibitor of DNMT1, MG98 (Plummer et al.,
2009), may be considered as FRDA therapeutic options in the
future.
HDAC INHIBITORS
HDAC inhibitors can affect transcription by increasing acetyla-
tion of histones, transcription factors, and other proteins that
regulate transcription (Butler and Bates, 2006). In view of the
recent identification of histone acetylation changes at the FXN
gene in FRDA, it has been proposed that the reversal of such his-
tone modifications could represent a useful therapeutic approach
for FRDA (Figure 3) (Festenstein, 2006; Herman et al., 2006).
An initial study to screen for frataxin-increasing compounds by
Sarsero and colleagues first demonstrated a small effect of the gen-
eral HDAC inhibitor sodium butyrate on FXN gene activity using
an EGFP reporter cell line (Sarsero et al., 2003). Subsequently,
Gottesfeld and colleagues treated FRDA lymphoblastoid cells
using a selection of commercially available HDAC inhibitors.
They revealed that only the benzamide compound BML-210 pro-
duced a significant increase of FXN mRNA expression (Herman
et al., 2006), although other HDAC inhibitors showed a more
pronounced increase of histone acetylation without any increase
in FXN expression, indicating a degree of compound specificity
for FXN gene silencing (Table 2). An analog of BML-210, des-
ignated 4b, was then synthesized and was shown to directly
modulate the histones associated with the FXN gene to increase
FXN mRNA expression in FRDA primary lymphocytes (Herman
et al., 2006). Compound 4b has subsequently been used to
demonstrate amelioration of the HD phenotype in R6/2 mice
without any discernible toxicity (Thomas et al., 2008). Further
development of HDAC inhibitors by the Gottesfeld lab and the
Repligen Corporation (Waltham, Massachusetts) identified three
2-aminobenzamide compounds, designated 106, 136, and 109,
which can each significantly increase FXN mRNA and frataxin
protein levels in FRDA cells with only a small effect on unaffected
control cells (reviewed in Soragni et al., 2012). The exact mech-
anism of action of the 2-aminobenzamide HDAC inhibitors in
FRDA is not known. However, compound 106 has been shown
to act as selective slow-on, slow-off, tight-binding inhibitor of
class I HDACs, with a preference for inhibition of HDAC3 (Chou
et al., 2008; Xu et al., 2009). Compounds 106, 136, and 109 have
undergone investigations to determine safety, efficacy and phar-
macokinetic profile in short-term treatments of FRDA patient
derived cells and KIKI knock-in mice (Chou et al., 2008; Rai et al.,
2008, 2010; Soragni et al., 2008; Xu et al., 2009), and a long-
term treatment in YG8R YAC transgenic mice (Sandi et al., 2011)
(Table 2). Compound 109, which emerged as the most promising
compound for FRDA treatment, has now been assessed in a phase
I clinical trial as RG2833 (Soragni et al., 2012) and further related
compounds are now under development.
Recently, the class III HDAC inhibitor nicotinamide (Ghosh
and Feany, 2004) has been shown to increase frataxin expres-
sion and decrease H3K9me3 and H3K27me3 at the FXN gene in
FRDA cells and mouse models and this compound is now in early
stage clinical trials (Chan et al., 2013) (Table 2). Furthermore,
other HDAC inhibitors such as sirtinol (Ota et al., 2006), split-
omicin (Biacsi et al., 2008), LBH589 (Garbes et al., 2009), and
oxamflatin (Kim et al., 1999) have shown positive effects in other
FIGURE 3 | Potential epigenetic-based therapies for FRDA. Large
GAA•TTC repeats in FRDA patients are associated with
heterochromatin mediated FXN gene silencing. The use of specific
HDAC inhibitors, HDM activators, HAT activators, HMTase inhibitors,
or agRNA activation may reverse the heterochromatin to a more
open chromatin structure, and may thus lead to active FXN gene
transcription. This image was adapted from Festenstein (2006); Chan
et al. (2013).
Frontiers in Genetics | Epigenomics and Epigenetics June 2014 | Volume 5 | Article 165 | 6
Sandi et al. Epigenetic-based therapies for Friedreich ataxia
Table 2 | HDAC inhibitor preclinical studies of FRDA cells and mice.
HDAC inhibitor FRDA test system FXN mRNA change Frataxin protein change Change in FXN histone
marks
References
Sodium butyrate FXN-EGFP reporter cell
line
1.16 fold ↑ (FXN-EGFP) Sarsero et al., 2003
Trichostatin A Lymphoblasts No change, 1.2 fold ↑ Herman et al., 2006
SAHA Lymphoblasts No change, 1.6 fold ↑ Herman et al., 2006
Oxamflatin Lymphoblasts 1.5 fold ↑ Herman et al., 2006
BML-210 Lymphoblasts 2.2 fold ↑ Herman et al., 2006
4b Primary lymphocytes 2.3 fold ↑ 3–3.5 fold ↑ 3 fold ↑ (H3K14ac, H4K5ac,
and H4K12ac)
Herman et al., 2006
Lymphoblasts 2.5 fold ↑
106 Primary lymphocytes 1.7–3.6 fold ↑ Rai et al., 2008, 2010;
Soragni et al., 2008;
Sandi et al., 2011
Lymphoblasts 2.6 fold ↑
KIKI mice 1.2–1.6 fold ↑ 1.4 fold ↑ 1.2–1.5 fold ↑ (H4K5ac,
H4K8ac, H4K16ac, and
H3K14ac)
FXN transgenic mice No change 1.6 fold ↑ 1.8–2 fold ↑ (H4K5ac)
136 Primary lymphocytes 1.2–2 fold ↑ Rai et al., 2010; Sandi
et al., 2011
KIKI mice 1.2 fold ↑ 1.2–1.5 fold ↑ (H3K14ac and
H4K5ac)
FXN transgenic mice No change 2 fold ↑ No change
109 Primary lymphocytes 2–8 fold ↑ 2–3.6 fold ↑ Rai et al., 2010; Sandi
et al., 2011
KIKI mice 1.2–1.3 ↑ 1.2–1.5 fold ↑ (H3K14ac and
H4K5ac)
FXN transgenic mice No change 2.6 fold ↑ 1.2–8 fold ↑ (H3K9ac, H4K5,
and H4K12ac)
Nicotinamide Lymphoblasts 1.06–1.8 fold ↑ 2 fold ↑ H3ac 1.8 fold ↑ H4ac Chan et al., 2013
Primary lymphocytes 4.5 fold ↑ 2.9 fold ↓ H3K9me3 and 1.56
fold ↓ H3K27me3
FXN YAC transgenic
mice
1.3–1.8 fold ↑ 2.1 fold ↓ H3K9me3 and 1.6
fold ↓ H3K27me3
C5 Lymphoblasts 2–3 fold ↑ (H3K9ac and
H4K8ac)
Lufino et al., 2013
Primary lymphocytes 1.5–2 fold ↑ Lufino et al., 2013
diseases including cancer and/or neurodegenerative disorders
and these compounds may also be considered for future FRDA
therapy. A number of research groups are also currently screen-
ing for novel frataxin-increasing compounds and one group
has identified a novel HDAC inhibitor, designated C5, which
upregulates FXN expression in FRDA patient primary lympho-
cytes and increases H3K9ac and H4K8ac in FRDA lymphoblasts
(Lufino et al., 2013) (Table 2). Interestingly, it has also recently
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been reported that resveratrol, a sirtuin activator, can produce a
marked increase in frataxin expression in a FXN-EGFP reporter
cell line and in a FRDA mouse model (Li et al., 2013). Therefore,
further studies are required to dissect the interplay of HDACs and
compounds that modulate HDAC activity in the direct or indirect
control of FXN gene expression. Epigenetic-based therapies for
FRDA are also likely to have other off-target effects, which do not
directly affect FXN gene regulation, but which may nevertheless
have other positive or negative effects on FRDA disease. For exam-
ple, recent studies have demonstrated that frataxin deficiency
in a conditional knockout mouse model triggers SIRT3 inhibi-
tion, resulting in marked hyperacetylation of numerous cardiac
mitochondrial proteins (Wagner et al., 2012) that may lead to
an increased sensitivity to oxidative stress. This finding suggests
that the compounds that specifically activate SIRT3 could be a
beneficial FRDA therapy.
HMTase INHIBITORS
HMTase inhibitors, which may induce a more open chromatin
structure at the FXN gene, are now also being considered for
FRDA therapy (Figure 3). For example GSK126 has been iden-
tified as a potent and highly specific inhibitor of EZH2, a
major component of the Polycomb repressor complex 2 (PRC2)
(McCabe et al., 2012). EZH2 trimethylates lysine 27 on the tail
of histone H3 (H3K27) and has been linked to the repression of
several genes, thus, inhibition of this repressive histone mark at
active genes could have a beneficial therapeutic outcome. High
throughput biochemical screening has revealed genome-wide loss
of H3K27 methylation and activation of previously silenced genes
with minimal off-target effects following treatment with GSK126
(McCabe et al., 2012). In addition, small cell lung cancer (SCLC)
cells treated with GSK126 showed substantial inhibition of cellu-
lar growth and this inhibition was concomitant with the reduced
levels of H3K27me3 (Sato et al., 2013). These findings have high-
lighted the fact that inhibition of EZH2 activity by small molecule
inhibitors, like GSK126, has a therapeutic benefit. In FRDA,
increased levels of H3K27me3 have been reported in lymphoblas-
toid cells and fibroblast cells (De Biase et al., 2009; Kim et al.,
2011; Chan et al., 2013) (Table 1). Therefore, this compound,
which can inhibit such repressive marks, could have a beneficial
FRDA therapeutic effect by reactivating FXN gene transcription.
Other studies have shown that H3K9me2 can be erased from
the promoters of reactivated tumor suppressor genes follow-
ing treatment with DNMTs and/or HDAC inhibitors (McGarvey
et al., 2006). Therefore, compounds which can reduce H3K9me2
levels are an attractive option where gene silencing involves
increased H3K9me2 levels, as seen with FRDA (Sandi et al., 2013)
(Table 1). This has led to the development of various compounds
that can inhibit the G9a activity directly or indirectly. The ini-
tial screening of 125,000 compounds from a chemical library has
identified BIX-01294 as a potent and specific inhibitor of G9a
(Kubicek et al., 2007). BIX-01294 binds to the SET domain of GLP
in the same groove at which the target lysine (H3K9) binds. This
prevents the binding of the peptide substrate and, consequently,
the deposition of methylation marks at H3K9 (Chang et al.,
2009). Recent studies in FRDA lymphoblastoid cells using the
HMTase inhibitor, BIX-01294, identified a significant reduction
in H3K9me2/me3, but without increasing the FXN mRNA levels,
suggesting a possible redundant role for H3K9me2/me3 in FXN
gene silencing (Punga and Buhler, 2010). In contrast, Chan and
colleagues have recently identified nicotinamide-induced reacti-
vation of the FXN gene in association with decreased H3K9me3
and H3K27me3 (Chan et al., 2013). Recently, a new inhibitor
for G9a and GLP, UNC0638, has been identified (Vedadi et al.,
2011). Treatment of a variety of cell lines with UNC0638 resulted
in lower global H3K9me2 levels and activated several previously
silenced genes in vitro (Vedadi et al., 2011). In addition, treatment
of U2OS and HeLa cells with UNC0638 has shown that it specif-
ically inhibits H3K9me2, with minimal effect on H3K27me3 and
H4Kme3 levels (Machleidt et al., 2011). ERG-associated protein
with SET domain (ESET), a novel histone H3K9 methyltrans-
ferase, has been shown to mediate histone methylation (Rea et al.,
2000). It is also proposed that ESET may have a role in epigenetic
silencing of neuronal genes through its HMTase activity (Li et al.,
2006). Importantly, the ESET levels were significantly elevated
in HD patients and in R6/2 transgenic mice (Ryu et al., 2006).
Subsequent treatment with mithramycin (or in combination with
cystamine), resulted in substantial reduction of H3K9me3 and
significantly improved the behavioral and neuropathological phe-
notype in R6/2 and 82Qmice of HD (Ryu et al., 2006; Stack et al.,
2007). Mithramycin is a clinically approved guanosine-cytosine
rich DNA antitumor antibiotic that interferes with the DNA bind-
ing of the Sp family transcription factors, but its effects in FRDA
have not yet been studied. Ongoing preclinical studies of cell and
mouse models using such HMTase inhibitors will determine if
any of these compounds can be considered suitable to progress
to FRDA clinical studies, as is the case now for HDAC inhibitors.
ANTIGENE RNA-BASED THERAPIES
Antigene RNAs (agRNAs) are small duplex RNAs of 19 bp in
length that target gene promoters. Depending on the target
sequence and cell type, agRNAs can either silence (Janowski
et al., 2006) or activate the gene transcription (Janowski et al.,
2007). Since agRNAs target in a sequence specific manner, it may
be possible to modulate agRNAs to activate gene expression in
disease-associated genes where gene activation is essential, as with
FRDA. Importantly, agRNAs can target both sense or antisense
strands, and coding or non-coding RNA transcripts (Watts et al.,
2010). Therefore, the use of agRNA to activate the FXN gene by
targeting the FXN promoter or the FAST1 transcript may prove
useful, since both mechanisms may be involved in reversing FXN
gene silencing and thus ameliorating FRDA disease. However,
as with any macromolecule-based therapy, the major problem
of how to achieve effective delivery to cells will first have to be
overcome.
POTENTIAL RISKS OF EPIGENETIC THERAPIES
Epigenetic therapies to date have primarily focused on the use of
DNA hypomethylating agents and HDAC inhibitors. The major
risk associated with any epigenetic therapy is the potential lack
of specificity. To the best of our knowledge it is not yet possi-
ble to silence or reactivate specific genes through use of DNMT
inhibitors or HDAC inhibitors. Due to the general effects of these
compounds, they tend to disrupt global DNA methylation and
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histone acetylation status. Genome-wide loss of DNA methyla-
tion has been shown to produce a high incidence of lymphomas
in mouse models (Gaudet et al., 2003), which raises the concern
of potential tumor formation in patients given DNA hypomethy-
lating treatments. HDAC inhibitors also have off-target effects
that may be difficult to detect, especially if they appear years
after the initial therapy. This is important, because most FRDA
patients are diagnosed before adulthood. Therefore, prolonged
HDAC inhibitor treatment in childhood may induce tumor for-
mation, for example, that is only apparent later in adulthood.
However, studies to date show that HDAC inhibitors are actually
reasonably well tolerated in the short term. They appear to have
less toxicity when used for cancer treatment than classical cyto-
toxic chemotherapeutic agents, but they are still prone to induce
primary clinical toxicities such as cardiac side effects, nausea,
vomiting, fatigue, and reduced blood cell counts (Subramanian
et al., 2010). The clinical use of HMTase inhibitors has not
advanced as far as the use of HDAC inhibitors, but HMTase
inhibitors are also expected to induce extensive gene expression
changes, and hence potential off-target effects. Having said this,
use of the HMTase inhibitor GSK126 for the treatment of lym-
phoma has been shown to exert minimal off-target effects despite
genome-wide changes in H3K27 methylation, which is somewhat
encouraging (McCabe et al., 2012).
CONCLUSIONS
Due to the identification of several associated epigenetic marks,
FRDA can now be considered as an epigenetic disease and
drug treatments are being developed to target these epige-
netic changes in attempts to ameliorate the disease phenotype.
However, epigenetic-based therapies are generally non-specific,
with off-target effects, and the development of drugs to more
specifically target the FXN locus may require further considera-
tion. Epigenetic-based therapies for FRDA will also benefit from
further understanding of how FXN gene expression is controlled.
For example, it has been recently reported that two transcription
factors, SRF and TFAP2, directly bind to the promoter region of
the human FXN gene and alter frataxin mRNA and protein levels
(Li et al., 2010). Small non-coding RNAs, such as microRNAs,
have also been implicated in several neurodegenerative disor-
ders including AD (Cogswell et al., 2008), HD (Lee et al., 2011),
and FRDA (Mahishi et al., 2012). An elevated level of miR-886-
3p in FRDA is associated with the downregulation of the FXN
gene and the use of anti-miR-886-3p or the HDAC inhibitor 4b
alone has been shown to partially reverse FXN gene repression
by reducing miR-886-3p levels (Mahishi et al., 2012; Bandiera
et al., 2013). Therefore, it would be interesting to investigate the
combined effect of anti-microRNA and HDAC inhibitor com-
pounds in the activation of FXN gene transcription. In general,
it may also be useful to simultaneously administer two or more
epigenetic-based drugs to examine synergistic treatment effects.
In addition, to identify novel epigenetic-based FRDA therapeu-
tic compounds, various drug-screening systems, cell and animal
models have been developed and are currently being utilized by
several labs (see review Martelli et al., 2012). Overall, considering
the rapid progress that has been made to take HDAC inhibitor
therapy from basic research to FRDA clinical trials, the next few
years will hopefully see the emergence of at least one effective
epigenetic-based therapy for FRDA.
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